Samsung Biologics agreed to acquire a U.S. drug production facility from GlaxoSmithKline for $280 million, a deal that expands the CDMO’s manufacturing footprint in North America. The transaction signals continued consolidation and capacity investment in biomanufacturing as demand for contract biologics production grows. For global pharma supply chains, the deal adds dedicated capacity for monoclonal antibodies and other complex biologics at a time when companies are seeking redundancy and regional sites to mitigate geopolitical and logistical risk.